Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy uncertainties. Read my earnings analysis.

VZ has provided FY 2025 guidance, projecting a 2-2.8% YoY growth in total wireless service revenues and 2-3.5% adj. EBITDA growth. The company projects higher capex for FY 2025, between $17.5 to $18.5 ...

AbbVie (ABBV) stock gains as company sets 2025 earnings outlook in line with expectations after Q4 revenue beat and despite quarterly loss. Read more here.

Conagra is showing signs of a turnaround with improving shipment volumes, organic sales growth, and a rising market share in its portfolio. Read more here.

Danone's shares have fallen by 13% over five years, but the company has improved significantly, increasing revenues and free ...

Shares of Colgate-Palmolive ( NYSE: CL) are trading defensively ahead of Friday’s opening bell as mixed fourth quarter results, including FY24 milestone revenue of $20B, were overshadowed by ...

TSMC's AI demand and robust financial health highlight its growth. Find out why TSM stock, along with DeepSeek’s ...

General Dynamics presents a compelling value opportunity amid recent share price weakness, despite strong operational ...

J. M. Smucker is undervalued at a forward PE of 10.7x, offering a solid 4.1% dividend yield with a well-covered 41% payout ...

Nothing stops the launch of many more meme coins; we are leaving the Fartcoin stage and entering the Trump (and Melania) memecoin stage. What will happen next?

Oil may be exempt from new tariffs despite President Trump's threats due to the complex nature of the U.S. energy industry.

XLV offers a rare combination of stability and growth potential through its diverse investments in the healthcare sector, justifying a buy rating. Explore more details here.